 Steven Schuster
Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 3 | 2013 | 93 | 0.850 |
Why?
| | Psychotherapy, Group | 1 | 2019 | 61 | 0.630 |
Why?
| | Exercise Therapy | 1 | 2019 | 351 | 0.500 |
Why?
| | Cancer Survivors | 1 | 2019 | 203 | 0.500 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1361 | 0.470 |
Why?
| | Peptide Hydrolases | 1 | 2013 | 109 | 0.420 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2010 | 11 | 0.370 |
Why?
| | Immunoglobulin M | 1 | 2010 | 254 | 0.330 |
Why?
| | Quality of Life | 1 | 2019 | 2385 | 0.310 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1147 | 0.310 |
Why?
| | Breast Neoplasms | 1 | 2019 | 1872 | 0.290 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2006 | 194 | 0.210 |
Why?
| | Metabolic Syndrome | 1 | 2006 | 324 | 0.210 |
Why?
| | Dexamethasone | 3 | 2013 | 316 | 0.200 |
Why?
| | Carcinoma, Renal Cell | 1 | 2023 | 168 | 0.190 |
Why?
| | Kidney Neoplasms | 1 | 2023 | 326 | 0.160 |
Why?
| | Insulin Resistance | 1 | 2006 | 1078 | 0.150 |
Why?
| | Prognosis | 3 | 2019 | 3339 | 0.140 |
Why?
| | Cyclophosphamide | 2 | 2012 | 218 | 0.120 |
Why?
| | Thalidomide | 1 | 2013 | 28 | 0.110 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2019 | 538 | 0.110 |
Why?
| | Survival Analysis | 2 | 2013 | 1219 | 0.110 |
Why?
| | Polycythemia Vera | 1 | 2012 | 13 | 0.110 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2013 | 139 | 0.100 |
Why?
| | Boronic Acids | 1 | 2012 | 33 | 0.100 |
Why?
| | Amyloidosis | 1 | 2012 | 36 | 0.100 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2011 | 18 | 0.100 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 80 | 0.100 |
Why?
| | Pyrazines | 1 | 2012 | 70 | 0.100 |
Why?
| | Multimodal Imaging | 1 | 2011 | 98 | 0.090 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 374 | 0.090 |
Why?
| | Aged | 4 | 2019 | 19251 | 0.090 |
Why?
| | Pulmonary Embolism | 1 | 2012 | 182 | 0.090 |
Why?
| | Translocation, Genetic | 1 | 2010 | 93 | 0.090 |
Why?
| | Clone Cells | 1 | 2010 | 248 | 0.090 |
Why?
| | Positron-Emission Tomography | 1 | 2011 | 284 | 0.090 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1357 | 0.090 |
Why?
| | Bone Diseases | 1 | 2010 | 58 | 0.090 |
Why?
| | Middle Aged | 5 | 2019 | 26999 | 0.080 |
Why?
| | Bone Marrow | 1 | 2010 | 249 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2013 | 638 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2019 | 9159 | 0.080 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 4665 | 0.070 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1048 | 0.070 |
Why?
| | Humans | 11 | 2023 | 115587 | 0.070 |
Why?
| | Cell Line, Tumor | 1 | 2013 | 2751 | 0.070 |
Why?
| | Survival Rate | 1 | 2010 | 1650 | 0.070 |
Why?
| | Lung Diseases | 1 | 2012 | 710 | 0.070 |
Why?
| | Lymphocyte Transfusion | 1 | 2005 | 19 | 0.070 |
Why?
| | CD28 Antigens | 1 | 2005 | 47 | 0.070 |
Why?
| | Remission Induction | 2 | 2019 | 240 | 0.060 |
Why?
| | CD8 Antigens | 1 | 2005 | 69 | 0.060 |
Why?
| | Autonomic Nervous System | 1 | 2006 | 70 | 0.060 |
Why?
| | Continuous Positive Airway Pressure | 1 | 2006 | 50 | 0.060 |
Why?
| | Stem Cell Transplantation | 1 | 2005 | 151 | 0.060 |
Why?
| | Lymphoma | 1 | 2005 | 178 | 0.060 |
Why?
| | Leukemia | 1 | 2005 | 209 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1893 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2392 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2006 | 677 | 0.050 |
Why?
| | Adult | 3 | 2019 | 30718 | 0.050 |
Why?
| | Glucose | 1 | 2006 | 904 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1137 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2019 | 105 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 667 | 0.040 |
Why?
| | Female | 4 | 2019 | 59913 | 0.040 |
Why?
| | Azacitidine | 1 | 2019 | 130 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2019 | 171 | 0.040 |
Why?
| | Genetic Testing | 1 | 2019 | 382 | 0.040 |
Why?
| | Sulfonamides | 1 | 2019 | 447 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 6417 | 0.030 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2013 | 58 | 0.030 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2013 | 46 | 0.030 |
Why?
| | Risk Factors | 1 | 2006 | 8697 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2012 | 29 | 0.030 |
Why?
| | Bortezomib | 1 | 2012 | 41 | 0.030 |
Why?
| | Vincristine | 1 | 2011 | 96 | 0.020 |
Why?
| | Amyloid | 1 | 2012 | 82 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 149 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4440 | 0.020 |
Why?
| | Doxorubicin | 1 | 2011 | 290 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2011 | 621 | 0.020 |
Why?
| | Diagnostic Imaging | 1 | 2012 | 296 | 0.020 |
Why?
| | Male | 4 | 2019 | 55949 | 0.020 |
Why?
| | Kidney | 1 | 2012 | 1207 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2005 | 397 | 0.010 |
Why?
| | Antigens, CD | 1 | 2005 | 442 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 4944 | 0.010 |
Why?
| | Lymphocyte Activation | 1 | 2005 | 1057 | 0.010 |
Why?
| | Time Factors | 1 | 2012 | 6165 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2012 | 12608 | 0.010 |
Why?
| | Adolescent | 1 | 2005 | 17889 | 0.000 |
Why?
| | Child | 1 | 2005 | 18488 | 0.000 |
Why?
|
|
Schuster's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|